|
16 Oct 2019 |
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
|
|
16 Oct 2019 |
Amphivena Initiates Solid Tumor Clinical Trial
|
|
16 Oct 2019 |
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
|
|
15 Oct 2019 |
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
|
|
15 Oct 2019 |
Affimed Reports Progress on Key Clinical Development Programs
|
|
15 Oct 2019 |
Immutep reports positive final efficacy data from TACTI-mel trial in melanoma
|
|
14 Oct 2019 |
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
|
|
14 Oct 2019 |
Femtogenix Presents Efficacy and Toxicity Data on Antibody Drug Conjugates Containing New Generation of DNA-binding Therapeutic Payloads
|
|
14 Oct 2019 |
Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
|
|
11 Oct 2019 |
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
|
|
10 Oct 2019 |
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
|
|
10 Oct 2019 |
Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
|
|
10 Oct 2019 |
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
|
|
09 Oct 2019 |
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
|
|
09 Oct 2019 |
Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma
|
|
09 Oct 2019 |
Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg
|
|
08 Oct 2019 |
ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
|
|
08 Oct 2019 |
Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
|
|
07 Oct 2019 |
Janssen Submits Application to U.S. FDA Seeking Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
|
|
04 Oct 2019 |
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
|
|
04 Oct 2019 |
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
|
|
04 Oct 2019 |
FASENRA (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™
|
|
03 Oct 2019 |
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
|
|
02 Oct 2019 |
Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
|
|
02 Oct 2019 |
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
|
